altRX vs Noom
altRX has an open FDA warning letter dated June 8, 2026. Noom has none. On brand-name tirzepatide pen, Noom costs $10,800 less a year at standing rates: $349 a month against $1,249 a month at altRX. It is one of two products the two sell at comparable terms.
To see where both sit among the other sellers, read our best weight-loss injection providers board.
The record
altRX / Noom
Featured pick (affiliate partner)
altRX
8.8/10
Noom
5.8/10
- RedRock Pharmacy503A
- Health Warehousetype not stated
- Precision Medicinetype not stated
- and 1 more
altRX is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Noom pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Noom 5.8). How we are paid
What the record shows
- 01
altRX has an open FDA warning letter dated June 8, 2026. Noom has none.
- 02
altRX names four pharmacies. Noom names no compounding pharmacy in our record.
- 03
On brand-name tirzepatide pen, Noom costs $10,800 less a year at standing rates: $349 a month against $1,249 a month at altRX. It is one of two products the two sell at comparable terms.
- 04
Only altRX lists a price for compounded tirzepatide injection and brand-name semaglutide pen.
- 05
altRX lists all 50 states. Noom publishes no state list.
Prices and terms, product by product
A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.
altRX
Noom
$89/moLower
$1,068 a year
$179/mo
$2,148 a year
$1,249/mo
$14,988 a year
$349/moLower
$4,188 a year
$149/mo
$1,788 a year
$1,149/mo
$13,788 a year
Read off each seller’s own pages. altRX: September 28, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.
The case for each
The case for altRX
8.8/10- $1,080 a year less on compounded semaglutide injection
- Sells compounded tirzepatide injection and brand-name semaglutide pen, which Noom does not price
- Names its compounding pharmacy
- Open FDA warning letter, June 8, 2026
The case for Noom
5.8/10- No FDA warning letter on record
- $10,800 a year less on brand-name tirzepatide pen
- Names no compounding pharmacy
- Publishes no state list
Scores
altRX 8.8 · Noom 5.8 out of 10. Six weighted parts.
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
The score is the same formula for every seller. Payment does not enter it. Method
altRX vs Noom: questions
Other sellers we are paid by
Affiliate partners outside this pair. Each has its own record and review, scored the same way.
- YourEra9.0
From $99/mo
Visit site - Wellorithm7.4
From $247/mo
Visit site - DudeMeds6.8
From $175/mo prepaid
Visit site
Sellers closest to these two
Matched on molecule, form and price. Every pair we list · The register
Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks